Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

This early-phase safety study is testing a triple combination of two experimental immune-boosting drugs (SL-T10 and GX-I7) alongside pembrolizumab (a well-known immunotherapy drug) for men with prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see if this combination is safe and tolerable. **You may be eligible if...** - You are a male aged 19 or older - You have been confirmed to have prostate cancer that has spread (to bones or soft tissue) and is no longer controlled by hormone therapy (testosterone below 50 ng/dL) - You have previously received docetaxel (a chemotherapy drug) plus at least one of: abiraterone acetate or enzalutamide - Your cancer has continued to progress despite prior treatment, shown by rising PSA levels, growing soft tissue tumors, or new bone lesions - You are on ongoing hormone-suppressing therapy **You may NOT be eligible if...** - You have an active autoimmune disease or are on immune-suppressing medications or steroids - You have had prior severe immune-related side effects from immunotherapy - You have uncontrolled brain metastases Talk to your doctor to see if this trial is right for you.